Drug Manufacturing

Yantai Luye, Chengdu Biostar partner to market anticancer drug in mainland China

Luye Pharma Group’s wholly owned subsidiary Yantai Luye Drugs Trading has collaborated with Beijing Biostar Pharmaceuticals’ subsidiary Chengdu Biostar Pharmaceuticals for marketing anticancer drug, Utidelone Injection, in Chinese mainland.

Alvotech, BiosanaPharma partner to develop biosimilar for Xolair

Biopharmaceutical company Alvotech and BiosanaPharma have signed an exclusive global licensing agreement for the co-development of a proposed biosimilar, AVT23 (also called BP001), to Xolair (omalizumab).

Ocugen to buy Liminal’s vaccine manufacturing facility in Canada

US-based Ocugen has signed a letter of intent (LOI) to acquire Liminal Biosciences’ manufacturing site located in Belleville, Ontario, Canada, for an undisclosed sum.

Amyris to buy women’s wellness firm MenoLabs

Synthetic biotechnology company Amyris has agreed to acquire MenoLabs, a menopause symptoms treatment company.

Pfizer and Biohaven close collaboration agreements

Pfizer has completed the collaboration transaction with Biohaven Pharmaceuticals to obtain rights to market the latter’s rimegepant and zavegepant outside of the US.

Ovid signs license deal with AstraZeneca to expand epilepsy drug pipeline

Ovid Therapeutics has signed a license agreement with AstraZeneca for a library of early-stage small molecules that target the KCC2 transporter.

Ascletis expands ritonavir oral tablets production amid Covid-19 surge

Ascletis Pharma is expanding the production of ritonavir oral tablets as well as the oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 virus amid the recent surge in Covid-19 cases.

Texas Children’s Hospital to launch protein sub-unit Covid-19 vaccine

Texas Children's Hospital and Baylor College of Medicine are set to launch Corbevax, a protein sub-unit Covid-19 vaccine in India, with plans to roll out in other underserved countries later.

Pfizer to deliver 2.5 million additional doses of Covid-19 pill to UK

Pfizer has signed an agreement to deliver an additional 2.5 million treatment courses of its investigational Covid-19 pill Paxlovid to the UK.